HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in ...

Gilead Sciences and Arcus Biosciences’ domvanalimab, one of the last anti-TIGIT antibodies still standing, has failed another ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

This article first appeared on GuruFocus. Arcus Biosciences Inc (NYSE:RCUS) is set to release its Q1 2026 earnings on May 5, 2026. The consensus estimate for Q1 2026 revenue is $0.03 billion, and the ...

GAAP revenue far exceeded expectations, reaching $160 million in Q2 2025, driven by a one-time $143 million GAAP catch-up related to program changes with Gilead. GAAP earnings per share reached ...

Arcus Biosciences (RCUS) stock drops as the company halts a late-stage trial for a lung cancer drug developed with Gilead Sciences (GILD). Read more here.

Wall Street expects a year-over-year increase in earnings on lower revenues when Arcus Biosciences, Inc. (RCUS) reports ...

Bill Grossman is leaving Arcus Biosciences to take up a position at Gilead, putting him in charge of the Big Pharma's collaboration with his former employers. Grossman is currently chief medical ...

82,997 shares were sold indirectly on Dec. 4, 2025, for a transaction value of ~$2.1 million based on a weighted average sale price of $24.71 per share. The sale represented 5.91% of total holdings, ...

Vancouver, British Columbia--(Newsfile Corp. - January 29, 2026) - Arcus Development Group Inc. (TSXV: ADG) ("Arcus" or the "Company") announces that it has completed a $2 million non-brokered unit ...